Jon Waataja, PhD
About Jon Waataja, PhD
Jon Waataja, PhD, serves as the Director of Research at ReShape Lifesciences Inc. He has extensive experience in neuroscience and biochemistry, having held various research positions at institutions such as the University of Minnesota and EnteroMedics.
Current Role at ReShape Lifesciences
Jon Waataja, PhD, serves as the Director of Research at ReShape Lifesciences Inc. since 2017. In this role, he focuses on innovative research and development initiatives aimed at improving health outcomes. His work involves the exploration of novel bio-electronic targets and algorithms to address unmet medical needs. He has been instrumental in advancing the company's research agenda and leading projects that align with its mission.
Previous Experience at University of Minnesota
Jon Waataja has a significant history with the University of Minnesota, where he held multiple positions. He was a Predoctoral Fellow from 2002 to 2007, followed by a Postdoctoral Fellowship from 2012 to 2014. Additionally, he worked as a Consultant from 2014 to 2017. His extensive experience at the university contributed to his expertise in neuroscience and research methodologies.
Experience at EnteroMedics
Jon Waataja worked at EnteroMedics in various capacities, including Director of Research for one month in 2017 and as a Research Scientist from 2007 to 2011 for four years. He also served as a Consultant from 2014 to 2017. His roles at EnteroMedics involved contributing to research efforts focused on medical devices and interventions.
Educational Background
Jon Waataja earned his PhD in Neuroscience from the University of Minnesota, where he studied from 2002 to 2007. Prior to that, he obtained a Bachelor’s Degree in Biochemistry from the University of St. Thomas, studying from 1998 to 2002. His educational background laid the foundation for his research career and expertise in the field.
Research Contributions and Grants
As a Principal Investigator, Jon Waataja leads an NIH SBIR grant focused on using neuromodulation as a treatment for Type 2 Diabetes. His research aims to develop innovative solutions for managing this condition, showcasing his commitment to advancing medical science and improving patient care.